IMPROVING THE BIOPHARMACEUTICAL PROPERTIES OF OXCARBAZEPINE BY CO-CRYSTALLIZATION TECHNIQUE

The present research utilises the crystal engineering technique to modify the physiochemical properties of Oxcarbazepine (OXCBZ), antiepileptic drug used for the treatment of partial seizures with or without secondary generalization in adults and children. Crystal engineering comprises rational design and modified fabrication crystal structures and hence offers manifold prospects to selectively improve the biopharmaceutical parameters of Oxcarbazepine on the basis of in depth knowledge of crystallization processes and molecular properties. Oxcarbazepine co-crystals were evaluated for parameters by visual morphology, differential scanning calorimetry, infrared spectroscopy, X-ray diffractometry. In vitro drug release testing of co-crystals showed an increase in drug release as compared to drug release from the pure drug.